Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 2005

View Archived Issues

Oncolytic effects result from NF-kappaB blockade

Hybridon and Novartis to develop TLR9 drug candidates for asthma and allergy

Dual targeting with quinolones reduces the emergence of resistant Staphylococcus aureus

Studies describe the potential use of vatalanib for allograft rejection

Pirfenidone shows promise for lung transplant-associated obliterative bronchiolitis

New data on the benefits of alprostadil in women with FSAD

Clinical evidence supports the use of ambrisentan in PAH

Promising results obtained with an oral formulation of treprostinil

Rimonabant under clinical evaluation for maintaining smoking cessation

New data on the effects of TH-9507 in COPD

New phase I study for CHIR-258 in multiple myeloma

Ferring submits IND for female infertility product

Angiotech licenses ChondroGEL to Histogenics for cartilage repair

Novartis inlicenses Anadys' ANA-975 for HCV

European orphan drug designation for Proxinium

Phase II study for Ventavis in pulmonary hypertension associated with IPF

DCVax-Brain cleared for phase II GBM trial

Phase II study for 131I-TM-601 in glioma

Novel antiinfective agents disclosed in recent patent literature

Phase III trials begin for epratuzumab in lupus

IR-103 to be studied in drug naive HIV patients

Albuferon enters phase II study in combination with ribavirin for HCV

Novel 5-HT2C receptor agonist developed at Lilly

Japanese approval for Navelbine for inoperable or recurrent breast cancer

First phase IIb data on the therapeutic E1 vaccine for HCV infection

Vernalis and Serono jointly discover new matrix metalloproteinase inhibitors

Results of phase Ia trial of CTA-018 in psoriasis reported

CTCE-0214 induces stem cell mobilization in a phase I study

INS-50589 Antiplatelet well-tolerated, pharmacologically active in phase I study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...